Correspondence 0001193125-23-239726 from Baudax Bio, Inc. (BXRXQ) (CIK 0001780097)
Baudax Bio, Inc. (BXRXQ) (CIK 0001780097)
Date: Sept. 21, 2023 · CIK: 0001780097 · Accession: 0001193125-23-239726
AI Filing Summary & Sentiment
File numbers found in text: 333-274349
Letter
Baudax Bio, Inc.
490 Lapp Rd.
Malvern, Pennsylvania 19355
September 21, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re:
Baudax Bio, Inc.
Registration Statement on Form S-1 (File No. 333-274349)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Baudax Bio, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-274349) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 9:30 AM, eastern time, on September 25, 2023, or as soon as thereafter as is practicable.
Please contact Jennifer Porter, Esq. of Goodwin Procter LLP, counsel to the Company, at (445) 207-7806 to provide notice of effectiveness, or if you have any questions or comments concerning this request.
[Remainder of the page intentionally left blank]
Very truly yours,
BAUDAX BIO, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Baudax Bio, Inc. 490 Lapp Rd. Malvern, Pennsylvania 19355 September 21, 2023 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Baudax Bio, Inc. Registration Statement on Form S-1 (File No. 333-274349) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Baudax Bio, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-274349) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 9:30 AM, eastern time, on September 25, 2023, or as soon as thereafter as is practicable. Please contact Jennifer Porter, Esq. of Goodwin Procter LLP, counsel to the Company, at (445) 207-7806 to provide notice of effectiveness, or if you have any questions or comments concerning this request. [Remainder of the page intentionally left blank] Very truly yours, BAUDAX BIO, INC. By: /s/ Gerri A. Henwood Name: Gerri A. Henwood Title: Chief Executive Officer Baudax Bio, Inc. — Acceleration Letter